SHELLEY SCHEKALL-CALDARERA: Open Payments
NPI 1871346619 · WICHITA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,270 in 109 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $1,125 · 2025 $2,270
Food & beverage: $2,160Education: $109
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $373 |
| Neurocrine BioSciences, Inc. | 15 | $315 |
| Otsuka America Pharmaceutical, Inc. | 13 | $303 |
| ABBVIE INC. | 22 | $298 |
| Teva Pharmaceuticals USA, Inc. | 5 | $287 |
| Lundbeck LLC | 14 | $156 |
| Corium, LLC | 10 | $138 |
| Axsome Therapeutics, Inc. | 5 | $115 |
| Bausch Health US, LLC | 3 | $69 |
| Almatica Pharma LLC | 3 | $64 |
Products named: REXULTI, FANAPT, INGREZZA, VRAYLAR, AUSTEDO XR, Azstarys, Auvelity, APLENZIN.
Industry payments across KS — which companies pay providers there.
